• Mobile Team Blood Drives

      Blood Transfusion Institute of Serbia, Svetog Save 39 Open from Monday to Friday, 7 - 19h, Saturday 8 -15hTransmobile at the Republic Square, Belgrade, every day except Sunday, 11 to 17 hEmergency Center – Voluntary blood donation unit, every day except Sunday, 9 to 16 h
      Погледајте даље »
    • Погледајте даље »
    • Professional education and Training

      Responsibilities and tasks of the Scientific Research and Education Service make up a significant part of the activities of the BTIS including:Scientific research activities Education activities Professional training Scientific research work at the BTIS includes activities significant for the BTIS and the Republic of Serbia as a whole. Its objective is to improve the activities of the BTIS in the framework of blood transfusion, related with the implementation of new methods in routine practice, improvement of the production processes, acquiring new knowledge in domain of transfusion medicine and associated medical disciplines. In accordance with the Act on Scientific Research Activities of the Republic of Serbia, health care professionals at the BTIS acquire academic qualifications and gain opportunities to take aprt in the projects financed by the Ministry of Science of the Republic of Serbia, depending on the scientific competence of each candidate. Besides possibility of participation in the projects financed by the Government of Serbia, internal projects are designed and carried out within the BTIS, significant for the improvement of blood transfusion service. Educational Activities at the BTIS are performed in compliabce with the legal regulations, BTIS Statute, Contracts signed by the BTIS and other educational institutions (Medical Faculty, University of Belgrade, Nurses and Technicians College and Secondary Medical School) and on the Decree of the Academic Council of the Faculty of Pharmacy and the Medical Academy, Belgrade, based on the decision made by the BTIS Stirring Committee.
      Погледајте даље »
  • Patients

    Ваша локација Blood Transfusion Institute of Serbia / Patients

    Blood Transfusion Treatment

    Blood transfusion s an n irreplaceable therapeutically method that for the time being does not have an adequate alternative. Blood contains a specific substance – haemoglobin, which binds oxygen and carries it to tissues by the precious red blood cells. When patient bleeds, red blood cells are lost, haemoglobin level is reduced, thus the capacity of oxygen transport is reduced and because of that, the most sensitive tissues, such as brain and heart are endangered. Blood is a biological substance rather than a classical medication and for that reason it cannot be standardized or used without a high level of precaution. Treatment of patients having deficiency of their own blood is still impossible without voluntary blood donors.  

    Safety of blood intended for transfusion 

    Blood intended for safe transfusion of patients must not contain viruses, causes of infectious diseases such as hepatitis and AIDS. That is why the blood of each donor, at each donation, undergoes specific testing procedures. Currently used tests are highly sophisticated so that the risk of infections transmission by blood can almost completely be neglected.

    Still, considering that new viruses that can be transmitted through blood are constantly being detected, even the most up to date testing does not provide absolute safety of patients treated by blood transfusion.

    Strategy for the reduction of the use of blood

    One of the ways to reduce the risk of the use of other person’s blood is AUTOLOGOUS  blood transfusion. In this for of blood transfusion both donor and recipient of blood are one person, more precisely, blood intended for transfusion is donor’s own blood. For example, prior to a preplanned surgical procedure, patient can donate his own blood to be stored before administration during the surgery, if necessary.   

    Another option is transfusion of a patient’s own blood collected, purified and administered back to the patient during the surgical intervention. This method is also known as the intraoperative blood salvage and it requires the use of special equipment. This kind of transfusion treatment cannot be used in anemic patients.

    Restrictive blood use strategy includes the administration of drugs that stimulate production of red blood cells. These new, expensive drugs are the most appropriate transfusion replacement in anemic patients, especially those undergoing hemodialysis.

    Nowadays, during some major open heart surgeries, special drugs which regulate blood coagulation process are also used. Their use is intended to prevent excessive bleeding of the patient in the course of surgery and in that way they reduce the requirement of blood for transfusion.

    Blood substitutes

    For many years scientists were trying to find substances similar to human red blood cells that could be oxygen carriers, without any risks for the patients. So far, two substances having the requested potential have been found. One of them is pure haemoglobin, and the other one is a compound termed as perfluorocarbon. These preparations are subject to continuous improvement, so that now the fourth generation of haemoglobin preparations is available, as well as the second generation of the perfluorocarbon.

    The first generation of haemoglobin preparations was prepared using outdated human red blood cells. The second one dealt with the highly purified haemoglobin taken from the bovine blood. The third generation introduced gelatinous particles which coated haemoglobin, imitating red blood cells. The last generation of haemoglobin is prepared by genetic engineering using primitive cells of bacteria and plants acting as small factories. Although the fourth generation preparations are completely safe and efficient in the oxygen transportation in patients with sudden blood loss, their clinical use has not been approved yet in any developed country. The only country in which the use of commercially prepared bovine haemoglobin was approved in 2001 was South Africa. 

    The other blood substitutes, perfluorocarbons (PFC), i.e. special compounds in which oxygen is extremely well dissolved and as such easily carried into tissues. Vey much like previously described preparations, according to clinical experience, PFCs also have their limitations. So far, only the Russian Ministry of Health has approved their use.

    Most up to date discovery

    On April 1st, 2007, Danish research team has published the discovery of two kinds of enzymes capable of turning A and B blood group red blood cells into O blood group red blood cells. This finding is significant, since O blood group can be considered universal and as such it can be used in cases of misbalanced blood stocks according to the actual requirements. The first research work in this field was initiated in 1980.